Your browser doesn't support javascript.
loading
Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial.
Zhang, Wenwen; Tong, Shuang; Hu, Bingyang; Wan, Tao; Tang, Haowen; Zhao, Feilong; Jiao, Tianyu; Li, Junfeng; Zhang, Ze; Cai, Jinping; Ye, Huiyi; Wang, Zhanbo; Chen, Shiqing; Wang, Yafei; Li, Xuerui; Wang, Fangzhou; Cao, Junning; Tian, Lantian; Zhao, Xiaochen; Chen, Mingyi; Wang, Hongguang; Cai, Shouwang; Hu, Minggen; Bai, Yuezong; Lu, Shichun.
Afiliación
  • Zhang W; Faculty of Hepato-Pancreato-Biliary Surgery, Chinese PLA General Hospital, Beijing, China.
  • Tong S; Institute of Hepatobiliary Surgery of Chinese PLA, Beijing, China.
  • Hu B; Key Laboratory of Digital Hepetobiliary Surgery of Chinese PLA, Beijing, China.
  • Wan T; Medical Affairs, 3D Medicines, Shanghai, China.
  • Tang H; Faculty of Hepato-Pancreato-Biliary Surgery, Chinese PLA General Hospital, Beijing, China.
  • Zhao F; Institute of Hepatobiliary Surgery of Chinese PLA, Beijing, China.
  • Jiao T; Key Laboratory of Digital Hepetobiliary Surgery of Chinese PLA, Beijing, China.
  • Li J; Faculty of Hepato-Pancreato-Biliary Surgery, Chinese PLA General Hospital, Beijing, China.
  • Zhang Z; Institute of Hepatobiliary Surgery of Chinese PLA, Beijing, China.
  • Cai J; Key Laboratory of Digital Hepetobiliary Surgery of Chinese PLA, Beijing, China.
  • Ye H; Faculty of Hepato-Pancreato-Biliary Surgery, Chinese PLA General Hospital, Beijing, China.
  • Wang Z; Institute of Hepatobiliary Surgery of Chinese PLA, Beijing, China.
  • Chen S; Key Laboratory of Digital Hepetobiliary Surgery of Chinese PLA, Beijing, China.
  • Wang Y; Medical Affairs, 3D Medicines, Shanghai, China.
  • Li X; Institute of Hepatobiliary Surgery of Chinese PLA, Beijing, China.
  • Wang F; Key Laboratory of Digital Hepetobiliary Surgery of Chinese PLA, Beijing, China.
  • Cao J; Medical School of Chinese PLA, Beijing, China.
  • Tian L; Institute of Hepatobiliary Surgery of Chinese PLA, Beijing, China.
  • Zhao X; Key Laboratory of Digital Hepetobiliary Surgery of Chinese PLA, Beijing, China.
  • Chen M; Medical School of Chinese PLA, Beijing, China.
  • Wang H; Institute of Hepatobiliary Surgery of Chinese PLA, Beijing, China.
  • Cai S; Key Laboratory of Digital Hepetobiliary Surgery of Chinese PLA, Beijing, China.
  • Hu M; Medical School of Chinese PLA, Beijing, China.
  • Bai Y; Medical Affairs, 3D Medicines, Shanghai, China.
  • Lu S; Department of Radiology, Chinese PLA General Hospital, Beijing, China.
J Immunother Cancer ; 11(9)2023 09.
Article en En | MEDLINE | ID: mdl-37730273
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudio: Prognostic_studies Límite: Adult / Humans Idioma: En Revista: J Immunother Cancer Año: 2023 Tipo del documento: Article País de afiliación: China
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudio: Prognostic_studies Límite: Adult / Humans Idioma: En Revista: J Immunother Cancer Año: 2023 Tipo del documento: Article País de afiliación: China